The Original Investigation titled “Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis,”1 published online March 28, 2024, and in the May 2024 issue was corrected to fix a spelling error in the eighth author's surname. The spelling for Bryan T. Carroll was corrected from “Carrol” to “Carroll.”
Reference
- 1.Mangla A, Lee C, Mirsky MM, et al. Neoadjuvant dual checkpoint inhibitors vs anti-PD1 therapy in high-risk resectable melanoma: a pooled analysis. JAMA Oncol. 2024;10(5):612-620. doi: 10.1001/jamaoncol.2023.7333 [DOI] [PMC free article] [PubMed] [Google Scholar]